|

Linvoseltamab Clinical Trials

14 actively recruiting trials across 7 locations

No change since August 2026

Also known as: Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5458, Anti-BCMA/CD3 Bispecific Antibody REGN5458, BCMA x CD3 Bispecific Antibody REGN5458, Linvoseltamab-gcpt, Lynozyfic +4 more

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 3Phase 4: 1Phase 1/2: 6

Top Sponsors

  • Regeneron Pharmaceuticals10
  • Dickran Kazandjian, MD2
  • Fred Hutchinson Cancer Center1
  • European Myeloma Network B.V.1

Indications

  • Cancer14
  • Multiple Myeloma6
  • Relapsed Refractory Multiple Myeloma (RRMM)3
  • High Risk Smoldering Multiple Myeloma (HR-SMM)1
  • Relapsed/Refractory Systemic Light Chain Amyloidosis1

Other3 trials

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2

Los Angeles, California3 trials

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

University of California Los Angeles (UCLA)

Phase 3
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

University of California Los Angeles (UCLA)

Phase 1/2
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Berenson Cancer Center

Phase 4

Miami, Florida3 trials

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

University of Miami

Phase 2
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

University of Miami

Phase 2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Sylvester Comprehensive Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Mayo Clinic Phoenix, Mayo Clinic Building

Phase 3

Duarte, California1 trial

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

City of Hope

Phase 1/2

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Baltimore, Maryland1 trial

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Johns Hopkins Hospital

Phase 2

Seattle, Washington1 trial

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.